Comment
Rifampicin is a potent inducer of hepatic microsomal enzymes and increases the oxidation of cortisol to 63-hydroxycortisol.2 As the major pathway of cortisol metabolism involving tetrahydroreduction of the A ring is not thought to be altered this increased utilisation usually represents only a small percentage of the cortisol produced in patients with normal adrenal function. In patients with pre-existing adrenal insufficiency, however, a higher and probably critical percentage may be involved. ' In both of our patients, who had adrenal insufficiency associated with tuberculosis, it is highly probable that rifampicin precipitated the acute adrenal crisis. In case 1 this occurred two weeks after beginning treatment (the time interval at which maximal enzyme induction is occurring)3 and unusually high doses of replacement therapy were required, while in case 2 the biochemical features of adrenal insufficiency improved when rifampicin was discontinued only to recur two weeks after it was reintroduced. Moreover 6 -hydroxycortisol excretion in case 1 was three to four times greater than that usually produced by therapeutic doses of rifampicin.2
To our knowledge the patient described by Edwards et all is the only other case in which rifampicin was thought to have induced an acute adrenal crisis. We emphasise the importance of considering adrenal insufficiency in all patients treated with rifampicin as adrenal crisis may occur within two weeks after beginning the drug even in those whose cortisol production is only mildly impaired (case 2). In addition, replacement therapy should be carefully monitored, as the standard doses of cortisone acetate and fludrocortisone may be inadequate (case 1).1 Other workers have also emphasised that patients receiving therapeutic doses of corticosteroids may need an increased dose when starting rifampicin.
We thank Dr C A Hopkins for allowing us to report the patient in case 2 and Dr K Park for measuring 6p-hydroxycortisol excretion in case 1 and for helpful advice. 
Pasteurella multocida endocarditis
Pasteurella multocida is found in the oral flora of most animals,' living most of its time as a commensal but capable of causing fatal haemorrhagic septicaemia in cattle.2 In recent years an increasing number of infections in man have been reported, causing a wide range of systemic illnesses. P multocida is a rare cause of infective endocarditis, and the following case is apparently the first to be reported in Britain.
Case report
A 50 year old painter and decorator was admitted to this hospital with a five day history of fever, shortness of breath, anorexia, and vomiting. Two days before admission he had started to become confused and had intermittent rigors and chills. He had had a non-productive cough a few days before the onset of his illness. Apart from pneumonia 25 years previously he had never had a serious illness. There was no history of recent travel or use of intravenous drugs. He had given up smoking six months previouslv after smoking 30 cigarettes daily for 30 years. He owned a dog.
On physical examination he was noted to be confused and disorientated. He was breathless with an irregular pulse of 120 beats/min. Temperature was 39 C and blood pressure 120/70 mm Hg. He was not jaundiced and had no lymphadenopathy, haemorrhages, or petechial spots. His left knee was swollen with some effusion. His heart was enlarged; the apex beat was in the anterior axillary line, and there was a grade 4/6 pansystolic murmur radiating to the axilla. Examination of chest and abdomen showed nothing abnormal, and the neurological findings were normal.
Results of initial laboratory evaluations included a haemoglobin concentration of 13-6 g/dl and white cell count of 18-3 x 109/1 with predominant neutrophils; platelet count was 84X 109/1. Blood urea concentration was 8-1 mmol/l (48-8 mg/100 ml), bilirubin concentration 22 Mumol/l (1-3 mg/100 ml), and albumin concentration 22 g/l (total protein 56 g/l, x-, and a2-globulins decreased) and serum alkaline phosphatase and aspartate aminotransferase activities normal. Electrocardiogram showed atrial fibrillation with rapid ventricular response and left ventricular hypertrophy. Chest x ray film showed cardiomegaly without any effusion of infiltrations.
A clinical diagnosis of acute infective endocarditis was made and specimens of blood (six sets), a throat swab, and midstream specimen of urine collected for culture. He was given digoxin to control ventricular rate. His blood cultures grew Grarns negative coccobacilli, which were identified as P multocida (later confirmed by the reference laboratory in Colindale). Initial sensitivity tests suggested treatment with ampicillin and gentamicin: later tests of minimal inhibitory concentrations of these drugs gave values of 0-25 and 2-0 mg/l respectively. He was treated with these antibiotics intravenously for three weeks, followed by intramuscular penicillin for one month. He required intermittent blood transfusions for his anaemia. Unfortunately, his left knee was not aspirated. The swelling in this joint gradually disappeared anda radiograph showed changes of osteoarthritis. Rheumatoid and antinuclear factors were not detected. His echocardiogram showed mitral incompetence with substantial regurgitation and left ventricular and left atrial enlargement.
After a prolonged illness his strength gradually increased and he was discharged from hospital after two months. Six weeks later he was seen in the outpatient clinic: his murmur was much less pronounced but he was still in atrial fibrillation with a ventricular rate of about 70 beats/min. He was followed up regularly, and one year after discharge he was quite well, mitral incompetence was stable, and there was no evidence of cardiac decompensation. He was still in atrial fibrillation and was taking digoxin and hydrochlorothiazide.
The patient lived near a farmyard, where he had handled sheep in the six months before the onset of his illness, so the source of infection might have been either his dog or the sheep. So far as we know these animals were quite well.
Comment
In 1878 Kitt first isolated a bacterium of the Pasteurella group during an epidemic in wild hogs.2 Two years later Pasteur described the organisms that caused fowl cholera, and subsequently the organism indistinguishable from those causing fowl cholera was found in rabbit septicaemia, swine plague, and haemorrhagic septicaemia of cattle.2 This organism is a small Gram negative coccobacillus which shows bipolar staining.
The range of infectiorn falls into three main types. The first is that where there is a definite history of animal bite or scratches-most commonly a cat bite. The usual manifestation is cellulitis with lymphadenitis, but osteomyelitis and distant metastatic infective foci may occur.' The second type is that associated with exposure to an infected animal. P multocida has been known to cause respiratory problems-for example, pneumonia-particularly in patients suffering from chronic respiratory illnesses such as chronic obstructive airways disease or bronchiectasis. Cases of peritonsillar abscess, empyema,3 fatal pulmonary abscess, and acute epiglottitis have been reported. The infection results from airborne or vector contact with the organism. Atraumatic exposure to animals has also led to pelvic and abdominal infection due to this organism causing peritonitis in the setting of cirrhosis, appendicitis, cervicitis, vaginitis, and chorioamnionitis.' The route of infection in this category is not known. The third category is where P miultocida infection has occurred without any animal exposure. This is the least common but, again, a wide variety of infection has been reported-for example, bronchitis, empyema, meningitis, cerebellar abscess, endocarditis, osteomyelitis, and polyarthralgia.' A unique outbreak of this infection in a chronic disease hospital was reported where epidemiological studies failed to determine the source.4
Person to person spread may occur since the organism may be part of normal human respiratory flora5; the infection appears to be due to opportunism rather than virulence. Penicillin is the drug of choice but strains resistant to penicillin have been reported. Erythromycin may be used in those patients allergic to penicillin. Cimetidine and metoclopramide in oesophageal reflux disease
Although cimetidine is effective in oesophageal reflux disease,' it is not as consistently useful as in peptic ulceration. Metoclopramide increases lower oesophageal sphincter pressure in normal subjects2 and patients with reflux: and speeds gastric emptying.4 These properties together with the acid lowering effect of cimetidine appeared to provide a sound rationale for combination therapy.
Patients, methods, and results
Seventy six patients with symptoms of oesophageal reflux entered a multicentre study. They were allocated at random to 12 weeks' treatment with cimetidine 400 mg three times daily with meals and at bedtime, with or without metoclopramide 10 mg three times daily with meals. All patients were supplied with Rennies as required for symptomatic relief. The double dummy technique was used to ensure that the study was double blind. Symptomatic and endoscopic assessment was carried out at the start of the study, symptoms were reassessed at 2, 4, 8, and 12 weeks, and a further endoscopy performed after 12 weeks. Grading, according to the endoscopic appearance of the oesophageal mucosa, was as follows: 0=-normal, 1-friability, 2= discrete lesions (erosions or multiple superficial ulcers), 3-confluent and longitudinal lesions, 4 circinate ulceration with or without complications. Endoscopic improvement was defined as a decrease of two grades or more at the second endoscopy compared with the first. Differences between the two treatments were analysed by Z2 tests and p accepted as significant at the 5", level.
Three patients were excluded from the analysis for deviating from the protocol; of the remainder, 40 received cimetidine alone and 33 the combination. The groups were well matched for age, sex, duration of disease, smoking, and alcohol consumption. The cimetidine group, however, contained significantly more patients with stenosis (6 v 0, p < 0-05). The two treatments did not differ in their relief of symptoms or effect on antacid consumption, although there was a non-significant trend towards decreased antacid consumption in patients taking the combination. The rapid relief of heartburn is illustrated in the figure, some two thirds of the patients becoming symptom free within the first week. Eighteen of the 33 patients receiving cimetidine (55") had healed or improved oesophagitis at the end of the trial compared with eight of 19 (42%(,) taking the combination (not significant).
A total of 32 adverse reactions were reported in 22 of the patients receiving the combination, while 16 patients receiving cimetidine alone reported 22 adverse events. Of these patients, 11 receiving the combination were withdrawn compared with three taking cimetidine (p< 001). Reasons for withdrawal of the 11 patients in the combination treatment group were vomiting and dizziness; somnolence (two cases); lethargy; nervousness and clumsiness; diarrhoea and lethargy; lethargy and depression; weakness, lethargy, and exhaustion; feeling of choking; "thick" speech and strange bodily sensation; and water brash and worsening of the stricture. The three patients in the cimetidine group were withdrawn complaining of epigastric pain, depression, and drowsiness and vomiting, respectively.
Comment
Although the effect on symptoms was comparable, the combination of metoclopramide and cimetidine appeared less effective in this study in producing endoscopic improvement and healing than cimetidine alone, although this difference did not reach statistical significance. A possible explanation might be that metoclopramide reduced the bioavailability of cimetidine.5 In our study adverse effects were certainly more common in patients receiving the combination and severe enough to necessitate withdrawal in one third. The results therefore suggest that, despite the plausible pharmacological rationale, there is no clinical advantage in coprescribing cimetidine and metoclopramide for oesophageal acid reflux disease. 
